Pyridostigmine for Myasthenia Gravis Q&A (1061)

Warning

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 06/12/2022

Next review date: 31/07/2025

Author(s): Laura Stobo.

Version: 1

Author email(s): laura.stobo@ggc.scot.nhs.uk.

Approved By: Medicines Utilisation Subcommittee of ADTC

Reviewer name(s): Laura Stobo.

Document Id: 1061